Prevention of ER-negative breast cancer: Where do we stand?

Research output: Contribution to journalArticle

Abstract

Oestrogen receptor-negative and triple-negative breast cancers are types of aggressive tumours that account for approximately 30 and 15% of total breast cancers, respectively. Selective oestrogen receptor modulators and aromatase inhibitors are unable to treat and prevent these subtypes of mammary tumours. Thus, it is worth identifying new pathways, biomarkers, and agents that are effective in the treatment and prevention of these subtypes. Several classes of drugs have been studied, and many are still currently under investigation. We have attempted to conduct a state-of-the-art study on this important issue.

Original languageEnglish
Pages (from-to)171-181
Number of pages11
JournalEuropean Journal of Cancer Prevention
Volume21
Issue number2
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Triple Negative Breast Neoplasms
Breast Neoplasms
Selective Estrogen Receptor Modulators
Aromatase Inhibitors
Estrogen Receptors
Biomarkers
Pharmaceutical Preparations
Neoplasms

Keywords

  • Breast cancer
  • Oestrogen receptor negative
  • Prevention

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Prevention of ER-negative breast cancer : Where do we stand? / Cazzaniga, Massimiliano; Bonanni, Bernardo.

In: European Journal of Cancer Prevention, Vol. 21, No. 2, 03.2012, p. 171-181.

Research output: Contribution to journalArticle

@article{d09dcd7441c8418991f6019d6466e475,
title = "Prevention of ER-negative breast cancer: Where do we stand?",
abstract = "Oestrogen receptor-negative and triple-negative breast cancers are types of aggressive tumours that account for approximately 30 and 15{\%} of total breast cancers, respectively. Selective oestrogen receptor modulators and aromatase inhibitors are unable to treat and prevent these subtypes of mammary tumours. Thus, it is worth identifying new pathways, biomarkers, and agents that are effective in the treatment and prevention of these subtypes. Several classes of drugs have been studied, and many are still currently under investigation. We have attempted to conduct a state-of-the-art study on this important issue.",
keywords = "Breast cancer, Oestrogen receptor negative, Prevention",
author = "Massimiliano Cazzaniga and Bernardo Bonanni",
year = "2012",
month = "3",
doi = "10.1097/CEJ.0b013e32834c9c26",
language = "English",
volume = "21",
pages = "171--181",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Prevention of ER-negative breast cancer

T2 - Where do we stand?

AU - Cazzaniga, Massimiliano

AU - Bonanni, Bernardo

PY - 2012/3

Y1 - 2012/3

N2 - Oestrogen receptor-negative and triple-negative breast cancers are types of aggressive tumours that account for approximately 30 and 15% of total breast cancers, respectively. Selective oestrogen receptor modulators and aromatase inhibitors are unable to treat and prevent these subtypes of mammary tumours. Thus, it is worth identifying new pathways, biomarkers, and agents that are effective in the treatment and prevention of these subtypes. Several classes of drugs have been studied, and many are still currently under investigation. We have attempted to conduct a state-of-the-art study on this important issue.

AB - Oestrogen receptor-negative and triple-negative breast cancers are types of aggressive tumours that account for approximately 30 and 15% of total breast cancers, respectively. Selective oestrogen receptor modulators and aromatase inhibitors are unable to treat and prevent these subtypes of mammary tumours. Thus, it is worth identifying new pathways, biomarkers, and agents that are effective in the treatment and prevention of these subtypes. Several classes of drugs have been studied, and many are still currently under investigation. We have attempted to conduct a state-of-the-art study on this important issue.

KW - Breast cancer

KW - Oestrogen receptor negative

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=84858298581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858298581&partnerID=8YFLogxK

U2 - 10.1097/CEJ.0b013e32834c9c26

DO - 10.1097/CEJ.0b013e32834c9c26

M3 - Article

C2 - 21968686

AN - SCOPUS:84858298581

VL - 21

SP - 171

EP - 181

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - 2

ER -